Skip to main content

Susan Kay Murphy, PhD

Murphy
Associate Professor in Obstetrics and Gynecology
Campus Mail: 701 W. Main Street, Suite 510, Room 5140, Durham, NC 27701
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

My research interests are largely centered around epigenetics and the role of epigenetic modifications in health and disease. My research projects include studies of gynecologic malignancies, including working on approaches to target ovarian cancer cells that survive chemotherapy and later give rise to recurrent disease.  I have ongoing collaborative projects in which we investigate the nature of the Developmental Origins of Health and Disease (DOHaD) hypothesis. DOHaD reflects the idea that our early environment plays an important part in shaping our risk of developing neurodevelopmental disorders or other chronic health problems. I am currently focused on preconception exposures in males with studies of the impact of cannabis use on the sperm epigenome and heritability of these effects. My lab is also working on the effects of in utero exposures, with our primary work revolving around the Newborn Epigenetics STudy (NEST), a mother-infant dyad cohort recruited from central North Carolina between 2005 and 2011 and whom we have followed since early pregnancy.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina - Charlotte, 1992

Selected Grants and Awards

Publications

Barnett, J. C., E. Kondoh, R. Whitaker, S. K. Murphy, and A. Berchuck. “High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S107–S107.

Scholars@Duke

Murphy, S. K., and L. Chen. “Imprinted Neuronatin: A potential epigenetie biomarker of ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S135–S135.

Scholars@Duke

Horne, Hisani N., Paula S. Lee, Susan K. Murphy, Miguel A. Alonso, John A. Olson, and Jeffrey R. Marks. “Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.” Mol Cancer Res 7, no. 2 (February 2009): 199–209. https://doi.org/10.1158/1541-7786.MCR-08-0314.

Full Text

Murphy, S. K., Z. Huang, Y. Wen, L. R. Simel, T. M. Price, and A. Berchuck. “Intragenic methylation at a novel CTCF binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S138–S138.

Scholars@Duke

Baba, T., H. S. Kang, N. Matsumura, J. Hamanishi, M. Mandai, A. Berchuck, S. K. Murphy, and I. Konishi. “Loss of GPR54 correlates with stem cell activity in high-grade endometrial cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S78–S78.

Scholars@Duke

Resnick, K. E., H. Alder, A Alvarez Secord, R. Whitaker, D. L. Richardson, C. Heaphy, S. K. Murphy, T. Baba, C. Croce, and D. E. Colin. “MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S115–16.

Scholars@Duke

Barnett, J. C., R. Whitaker, E. Kondoh, T. Baba, S. K. Murphy, and A. Berchuck. “Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S11–S11.

Scholars@Duke

Barnett, J. C., E. Iverson, H. Dressman, R. Whitaker, S. K. Murphy, J. Lancaster, and A. Berchuck. “Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S123–24.

Scholars@Duke

Matsumura, Noriomi, Zhiqing Huang, Tsukasa Baba, Paula S. Lee, Jason C. Barnett, Seiichi Mori, Jeffrey T. Chang, et al. “Yin yang 1 modulates taxane response in epithelial ovarian cancer.” Mol Cancer Res 7, no. 2 (February 2009): 210–20. https://doi.org/10.1158/1541-7786.MCR-08-0255.

Full Text

Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, E. Kondoh, T. Perry, Z. Huang, et al. “Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.” Oncogene 28, no. 2 (January 15, 2009): 209–18. https://doi.org/10.1038/onc.2008.374.

Full Text

Pages